$FBLG
FibroBiologics, Inc. Stock $fblg

$fblg Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019225 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.249M	$2.490M
YoY Change	-32.6%
% of Gross Profit
Research & Development	$975.0K	$960.0K	$478.0K
YoY Change	-4.51%	100.84%
% of Gross Profit
Depreciation & Amortization	$37.00K	$35.00K	$1.000K
YoY Change	1133.33%	3400.0%
% of Gross Profit
Operating Expenses	$3.224M	$3.450M	$2.265M
YoY Change	-26.02%	52.32%
Operating Profit	-$3.224M	-$3.450M	-$2.265M
YoY Change	54.04%	52.32%
Interest Expense	$5.000K	$4.000K	$135.0K
YoY Change	-103.42%	-97.04%
% of Operating Profit
Other Income/Expense, Net	$30.00K		-$15.00K
YoY Change	-141.67%
Pretax Income	$898.0K	-$8.460M
YoY Change	-119.62%
Income Tax
% Of Pretax Income
Net Earnings	$898.0K	-$8.460M	-$2.415M
YoY Change	-112.56%	250.31%
Net Earnings / Revenue
Basic Earnings Per Share	$0.03	-$0.27	-$0.18
Diluted Earnings Per Share	$0.03	-$0.27	-$0.18
COMMON SHARES
Basic Shares Outstanding	32.72M shares	32.63M shares	28.23M shares
Diluted Shares Outstanding	32.72M shares	31.13M shares	28.23M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.973M	$8.158M
YoY Change	-47.5%
Cash & Equivalents	$5.973M	$8.158M	$14.74M
Short-Term Investments
Other Short-Term Assets	$18.00K	$18.00K
YoY Change	-95.29%
Inventory
Prepaid Expenses	$518.0K	$746.0K
Receivables
Other Receivables
Total Short-Term Assets	$6.509M	$8.922M
YoY Change	-44.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$799.0K	$770.0K
YoY Change	-61.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.403M	$2.477M
YoY Change	15.31%
TOTAL ASSETS
Total Short-Term Assets	$6.509M	$8.922M
Total Long-Term Assets	$2.403M	$2.477M
Total Assets	$8.912M	$11.40M
YoY Change	-35.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.208M	$814.0K
YoY Change	102.01%
Accrued Expenses	$382.0K	$372.0K
YoY Change	11.05%
Deferred Revenue	$1.500M
YoY Change
Short-Term Debt	$287.0K	$459.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.13M	$13.99M
YoY Change	975.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.167M	$1.277M
YoY Change	-24.66%
Total Long-Term Liabilities	$1.167M	$1.277M
YoY Change	-24.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.13M	$13.99M
Total Long-Term Liabilities	$1.167M	$1.277M
Total Liabilities	$11.30M	$15.26M
YoY Change	353.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$31.92M	-$32.82M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.387M	-$3.863M	$639.0K
YoY Change
Total Liabilities & Shareholders Equity	$8.912M	$11.40M
YoY Change	-35.63%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$898.0K	-$8.460M	-$2.415M
YoY Change	-112.56%	250.31%
Depreciation, Depletion And Amortization	$37.00K	$35.00K	$1.000K
YoY Change	1133.33%	3400.0%
Cash From Operating Activities	-$1.947M	-$4.275M	-$2.036M
YoY Change	-46.82%	109.97%
INVESTING ACTIVITIES
Capital Expenditures	$66.00K	$8.000K	$56.00K
YoY Change	-17.5%	-85.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$66.00K	-$8.000K	-$56.00K
YoY Change	-17.5%	-85.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-172.0K	$3.278M	$14.57M
YoY Change	-101.34%	-77.5%
NET CHANGE
Cash From Operating Activities	-1.947M	-$4.275M	-$2.036M
Cash From Investing Activities	-66.00K	-$8.000K	-$56.00K
Cash From Financing Activities	-172.0K	$3.278M	$14.57M
Net Change In Cash	-2.185M	-$1.005M	$12.47M
YoY Change	-123.98%	-108.06%
FREE CASH FLOW
Cash From Operating Activities	-$1.947M	-$4.275M	-$2.036M
Capital Expenditures	$66.00K	$8.000K	$56.00K
Free Cash Flow	-$2.013M	-$4.283M	-$2.092M
YoY Change	-46.19%	104.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001958777
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2024Q1	FBLG	Net Parent Investment NetParentInvestment		usd
CY2023Q4	FBLG	Net Parent Investment NetParentInvestment		usd
CY2023Q1	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
CY2023Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts		usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2024Q1	FBLG	Deemed Dividend DeemedDividend		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2023Q1	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
CY2024Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative		usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2024Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables		usd
CY2023Q1	FBLG	Gain Loss On Change In Commitment Fee Payable GainLossOnChangeInCommitmentFeePayable		usd
CY2023Q1	FBLG	Increase Decrease In Change In Payable To Parent IncreaseDecreaseInChangeInPayableToParent		usd
CY2024Q1	FBLG	Rofn Agreement Payments To Parent RofnAgreementPaymentsToParent		usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2024Q1	FBLG	Proceeds From Stock Subscription Payable ProceedsFromStockSubscriptionPayable		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2023Q1	FBLG	Proceeds From Issuance Of Preferred Stock And Preference Stock1 ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	FBLG	Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest		usd
CY2024Q1	FBLG	Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock		usd
CY2024Q1	FBLG	Deemed Dividend DeemedDividend		usd
CY2024Q1	FBLG	Liability Instrument Fair Value LiabilityInstrumentFairValue		usd
CY2024Q1	FBLG	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41934
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	FibroBiologics, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3329066
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 E. Medical Center Blvd
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77598
CY2024Q1	dei	City Area Code CityAreaCode	(281)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	651-5150
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	FBLG
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32719125	shares
CY2024Q1	FBLG	Liability Instrument LiabilityInstrument	10340000	usd
CY2023Q4	FBLG	Liability Instrument LiabilityInstrument	7236000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	459000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13985000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9183000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1277000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1385000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	15262000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10568000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28954000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25609000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32817000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24357000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-3863000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1253000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11399000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11821000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	960000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	478000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2490000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1787000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	3450000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2265000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3450000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2265000	usd
CY2024Q1	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	3104000	usd
CY2024Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1941000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	39000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	4000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	135000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8460000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2415000	usd
CY2023Q1	FBLG	Deemed Dividend DeemedDividend	-2573000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8460000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4988000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31133762	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31133762	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1253000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	45000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2819000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	480000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8460000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-3863000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3996000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3996000	usd
CY2023Q1	FBLG	Stock Issue During Period Value Sale Of Preferred Stock Net Of Direct Costs StockIssueDuringPeriodValueSaleOfPreferredStockNetOfDirectCosts	4889000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4286000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	2573000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	448000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2415000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	639000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	639000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8460000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2415000	usd
CY2024Q1	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	3104000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	525000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	448000	usd
CY2023Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	15000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	78000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	102000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	95000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	35000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	275000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	710000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	20000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	71000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-630000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	197000	usd
CY2024Q1	FBLG	Gain Loss On Change In Commitment Fee Payable GainLossOnChangeInCommitmentFeePayable	-2000000	usd
CY2024Q1	FBLG	Increase Decrease In Change In Payable To Parent IncreaseDecreaseInChangeInPayableToParent	-141000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-98000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-89000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4275000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2036000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56000	usd
CY2023Q1	FBLG	Rofn Agreement Payments To Parent RofnAgreementPaymentsToParent	323000	usd
CY2024Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	574000	usd
CY2024Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	115000	usd
CY2023Q1	FBLG	Proceeds From Stock Subscription Payable ProceedsFromStockSubscriptionPayable	10000000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4889000	usd
CY2024Q1	FBLG	Proceeds From Issuance Of Preferred Stock And Preference Stock1 ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1	2819000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3278000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14566000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1005000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12474000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9163000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2266000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8158000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14740000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
CY2023Q1	FBLG	Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest	3823000	usd
CY2023Q1	FBLG	Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock	463000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32817000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8158000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2819000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2819000	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-4 shares
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zzX15Yqb3Xqj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Unaudited Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Unaudited Condensed Financial Statements; therefore, actual results could differ from those estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zwzxhtGg8LSd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_pn3d_c20240331_zpb2tP0ySn2g" title="Federally insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6039000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8460000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2415000	usd
CY2023Q1	FBLG	Deemed Dividend DeemedDividend	-2573000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8460000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4988000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31133762	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31133762	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	5600000	usd
CY2022Q4	FBLG	Capital Stock In Excess CapitalStockInExcess	10000000	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1900000	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	268192	shares
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	852000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	844000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	82000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	770000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	797000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	35000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q4	FBLG	Liability Instrument LiabilityInstrument	7236000	usd
CY2024Q1	FBLG	Warrant Liability WarrantLiability	20963000	usd
CY2024Q1	FBLG	Warrant Liability WarrantLiability	10340000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6039000	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	6039000	usd
CY2024Q1	FBLG	Warrant Liability WarrantLiability	10340000	usd
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	10340000	usd
CY2023Q4	FBLG	Liability Instrument Fair Value LiabilityInstrumentFairValue	7236000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	7236000	usd
CY2023Q4	us-gaap	Share Price SharePrice	15.00
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	51250	shares
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	168000	usd
CY2023Q1	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	35000000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	FBLG	Description Of Share Subscription Agreement DescriptionOfShareSubscriptionAgreement	The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee was due to the investors if the Company were sold in a private sale transaction rather than completing a public listing of its shares.
CY2024Q1	FBLG	Commitment Fee Payable CommitmentFeePayable	2000000	usd
CY2024Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1941000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	6000	usd
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	7000	usd
CY2024Q1	us-gaap	Payments For Rent PaymentsForRent	8000	usd
CY2024Q1	us-gaap	Payments For Rent PaymentsForRent	155000	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	173000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	347000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	488000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	544000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	509000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1888000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	239000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1649000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	372000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1277000	usd
CY2022	FBLG	Payments For Equity Investments PaymentsForEquityInvestments	323000	usd
CY2023Q1	FBLG	Payments For Equity Investments PaymentsForEquityInvestments	2265000	usd
CY2023Q1	FBLG	Percentage Of Gross Proceeds From Equity Investments PercentageOfGrossProceedsFromEquityInvestments	0.15	pure
CY2023Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	15000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	101250	shares
CY2022Q3	us-gaap	Share Price SharePrice	3.28
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3689750	shares
CY2023Q1	us-gaap	Share Price SharePrice	2.28
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2500	shares
CY2023Q3	us-gaap	Share Price SharePrice	3.28
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	216875	shares
CY2024Q1	us-gaap	Share Price SharePrice	13.00
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8494625	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8711500	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	480000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	448000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	480000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6899000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.042	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0389	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.97	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.79

Files In Submission

Name	View Source	Status
0001493152-24-019225-index-headers.html	Edgar Link	pending
0001493152-24-019225-index.html	Edgar Link	pending
0001493152-24-019225.txt	Edgar Link	pending
0001493152-24-019225-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
fblg-20240331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
fblg-20240331_cal.xml	Edgar Link	unprocessable
fblg-20240331_def.xml	Edgar Link	unprocessable
fblg-20240331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
fblg-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBLG
FibroBiologics, Inc. Stock $fblg

2024 Q2 Form 10-Q Financial Statement

#000149315224019225 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBLG FibroBiologics, Inc. Stock $fblg

2024 Q2 Form 10-Q Financial Statement

#000149315224019225 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBLG
FibroBiologics, Inc. Stock $fblg